Combination of Superficial and Deep Blocks with XXXX .

@entity1 @entity548 @entity1410 @entity3925 @entity616
OBJECTIVE: @entity3925 is a new Xa inhibitor indicated for thromboprophylaxis in @entity1 undergoing joint arthroplasty. This study was designed to assess the risk of major @entity548 from the combination of either a single or a continuous deep, superficial, and @entity616 and the use of @entity3925 for thromboprophylaxis following joint arthroplasty. METHOD: @entity1 undergoing either primary, redo, unilateral, or bilateral total hip or knee replacement while receiving a femoral, sciatic, lumbar @entity616 alone or in combination and receiving at least one dose of @entity3925 10 mg once a day for thromboprophylaxis postoperatively were included in this analysis. RESULTS: In this series, 766 @entity1 (199 total hip replacements and 567 total knee replacements) were included. A total of 1,104 blocks were performed including 1,029 continuous blocks (509 femoral, 320 sciatic, and 200 lumbar plexus). No major @entity548 related to the performance of peripheral nerve blocks was recorded. In contrast, three @entity1 developed @entity1410 in the operated knee requiring a surgical evacuation. @entity548 was recorded at the surgical site in 12 @entity1 vs 10 @entity1 at the site of the block. Although all minor @entity548 at the surgical site occurred after the initiation of the @entity3925 therapy, 80% of minor @entity548 at the site of the block was recorded before the initiation of thromboprophylaxis. CONCLUSION: Our data supports the concept that there is no increased risk of major @entity548 when deep and superficial blocks are performed in combination in @entity1 receiving thromboprophylaxis @entity3925 following joint arthroplasty.
